SLG
BLUE

Stanley-Laman Group’s bluebird bio BLUE Stock Holding History

Stanley-Laman Group’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-148
Closed -$243K – 268
2019
Q2 		$243K Buy
+148
New +$256K 0.06% 253
2019
Q1 		– Sell
-156
Closed -$201K – 260
2018
Q4 		$201K Buy
+156
New +$239K 0.06% 240
2018
Q3 		– Sell
-337
Closed -$686K – 223
2018
Q2 		$686K Buy
+337
New +$768K 0.15% 190

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Stanley-Laman Group's BLUE Position: Q3 2019 in Review

Stanley-Laman Group sold out of bluebird bio (BLUE) in Q3 2019, closing a stake of 148 shares — an estimated $243K sold.

Stanley-Laman Group first reported a position in BLUE in Q2 2018 and held it in 3 quarters. The position peaked at $686K in Q2 2018. 241 funds tracked by Wall St. Rank hold BLUE as of Q3 2019.

  • Stanley-Laman Group reported no remaining bluebird bio position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 148 bluebird bio shares in Q3 2019, an estimated $243K.
  • Stanley-Laman Group first reported a position in bluebird bio in Q2 2018 and held it in 3 quarters.
  • Stanley-Laman Group's bluebird bio position peaked at $686K in Q2 2018.
  • 241 funds tracked by Wall St. Rank held bluebird bio as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.